Company Overview and News
International engineering and operations support services contractor ODE, an integral part of the DORIS Group, has been awarded a contract to act as Pipeline Operator on behalf of Independent Oil and Gas Plc (IOG) for the Thames Pipeline that will serve the Blythe Hub and Vulcan Satellites Hub Developments.
NAIROBI, April 13 (Reuters) - Kenya's National Oil Corporation and U.S. oil services company Schlumberger have agreed to finalise a field development plan on behalf of the government for oil blocks in the northwest of the country.
NAIROBI (Reuters) - Kenya’s National Oil Corporation and U.S. oil services company Schlumberger have agreed to finalize a field development plan on behalf of the government for oil blocks in the northwest of the country.
KAMPALA, April 10 (Reuters) - Uganda signed an agreement on Tuesday with a consortium, including a subsidiary of America's General Electric, to build and operate an oil refinery in western Uganda that will cost $3 billion-$4 billion, the president's office said.
(Bloomberg) -- Exxon Mobil Corp. got such a “favorable” deal from Guyana, home to the biggest new deepwater oil play, that the tiny South American country should rewrite its tax laws, the International Monetary Fund said.
HOUSTON (Bloomberg) -- ExxonMobil got such a “favorable” deal from Guyana, home to the biggest new deepwater oil play, that the tiny South American country should rewrite its tax laws, the International Monetary Fund said.
16 March 2018 - Tullow Oil plc (“Tullow” or the “Company”) is pleased to announce that it has priced its offering of $800 million aggregate principal amount of 7% senior notes due 2025 at par (the “Notes”). The size of the offering has been increased from $650 million, indicated at launch on 12 March, to $800 million. Interest will be payable semi-annually. The offering is expected to complete on or about 23 March 2018, subject to customary conditions precedent for similar transactions.
Tullow Oil will continue to drive to reset its balance sheet after a tough three year downturn by selling $650m (£470m) of bonds to cover its 2020 debt repayments.
Tullow Oil plc (“Tullow” or the “Company”) today announces that it intends to offer $650 million in aggregate principal amount of senior notes due 2025 (the “Notes”).
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
The completion of Neptune Energy's acquisition of Engie E&P International SA follows a trend of private equity-backed companies purchasing legacy E&P assets, but this transaction, which all-but removes Engie from the upstream sector, is on a much larger scale. Neptune Energy's portfolio is larger than those of major independents such as Tullow Oil and Premier Oil, and of a similar scale to that of Perenco, according to GlobalData, a leading data and analytics company.
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 28, 2018) - Africa Oil Corp. ("Africa Oil" or the "Company") (TSX:AOI)(OMX:AOI) is pleased to announce its financial and operating results for the three months and year ended December 31, 2017.
LONDON -- Analysis of Ghana’s upstream oil and gas industry shows that the country currently has 21 licensed blocks, of which 14 are in the ultra-deepwater terrain, five are in shallow water, and two in deepwater, according to GlobalData, a leading data and analytics company.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...